Akebia Therapeutics Granted US Regulatory Clearance for Vafseo (vadadustat) Pills, a New Therapy for Adult Anemia Linked to Long-term Renal Failure in Dialysis Patients.

Viking Therapeutics Reports Outcomes of Initial Human Study for Oral Pill Version of Combined GLP-1/GIP Agonist VK2735.

TiumBio Lodges Application for Phase 1b Study of Prolonged-Effect Factor VII Agent TU7710 in Subjects with Hemophilia A/B.

First Subject Receives Initial Treatment in Innovent's Phase III Trial (Neoshot) Evaluating IBI310 (Anti-CTLA-4) with Sintilimab in Pre-Surgery Treatment for High Microsatellite Instability/Mismatch Repair Deficient Colon Cancer.

Tectonic Therapeutics Commences First-Stage Clinical Trial Evaluating TX45 in Category II Lung High Blood Pressure among Subjects Having Conserved Ejection Fraction Cardiac Insufficiency.

FDA Regulators Greenlight Merck's Novel WINREVAIR™ (sotatercept-csrk) Therapy for Treating Pulmonary Arterial Hypertension in Adult Patients.

Atamyo Pharma Secures Approval from European Regulators to Commence Human Trials of ATA-200, Their Innovative Genetic Treatment for Limb-Girdle Muscular Dystrophy 2C/R5.

CinFina Pharma Reveals US Health Authority's Approval for Early-Stage Drug Trial and Commencement of Dosing in Initial Human Subjects for its Obesity Medication, CIN-110.

Astellas Pharma Inc. announced that Japan's Ministry of Health, Labour and Welfare approved VYLOY™ (zolbetuximab), an anti-CLDN18.2 drug, for advanced and inoperable metastatic stomach cancer patients positive for CLDN18.2.

Initial enrollment of patients with stomach and esophageal cancer has begun for a second-stage mixed studies trial, utilizing Affibody's ABY-025 diagnostic tool for positron emission tomography.

Corteria Pharmaceuticals has launched the first stage of clinical trials to assess the efficacy of their CRF2 activator, COR-1167, specifically targeting the progression of cardiac insufficiency.

Intravacc, a globally recognized pioneer in the field of translational research as well as the creation of vaccines for both prevention and treatment, has shared encouraging results from initial human trials of Avacc 10.